Search
Anti-SARS-CoV-2 IgY
go.drugbank.com/drugs/DB16356InvestigationalAnti-SARS-CoV-2 IgY are chicken egg antibodies to SARS-CoV-2 which have the potential to provide temporary protection against the virus when administered as intranasal drops.
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU). CoFactor use with 5-FU is being evaluated in cli...
AVR118
go.drugbank.com/drugs/DB04979InvestigationalThis non-toxic peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human
BBV152
go.drugbank.com/drugs/DB15847InvestigationalThus, as of July 2020, BBV152 is in Phase 1/2 clinical trials assessing safety and immunogenicity in humans (NCT04471519).
Bexotegrast
go.drugbank.com/drugs/DB16515InvestigationalThe compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical
Lesopitron
go.drugbank.com/drugs/DB04970ExperimentalLesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.
Inbakicept
go.drugbank.com/drugs/DB16479InvestigationalInbakicept is a dimeric human IL-15 receptor α (IL-15Rα) sushi domain/human IgG1 Fc fusion protein. It is one of the active ingredients in Anktiva, a combination product also containing nogapendekin alfa, where a single inbakicept is com...
Ligelizumab
go.drugbank.com/drugs/DB11856InvestigationalSimilar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer
AP5346
go.drugbank.com/drugs/DB04992InvestigationalAP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
INCB7839
go.drugbank.com/drugs/DB05033InvestigationalINCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. It represents a potentially important new class of targeted breast cancer therapy. ...